Review Article

Reactive Astroglialesis: Implications in Spinal Cord Injury Progression and Therapy

Xinyu Li, Meng Li, Lige Tian, Jianan Chen, Ronghan Liu, and Bin Ning

Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, No. 105, Jiefang Road, Jinan, Shandong 250013, China

Correspondence should be addressed to Bin Ning; ningbin@sdu.edu.cn

Received 10 February 2020; Revised 6 May 2020; Accepted 31 July 2020; Published 20 August 2020

Academic Editor: Nageswara Madamanchi

Copyright © 2020 Xinyu Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Astrocytes are the most populous glial cells in the central nervous system (CNS). They are essential to CNS physiology and play important roles in the maintenance of homeostasis, development of synaptic plasticity, and neuroprotection. Nevertheless, under the influence of certain factors, astrocytes may also exert detrimental effects through a process of reactive astrogliosis.

Previous studies have shown that astrocytes have more than one type of polarization. Two types have been extensively researched. One is a damaging change that occurs under inflammation and has been termed A1 astrocyte, while the other is a restorative change that occurs under ischemic induction and was termed A2 astrocyte. Researchers are now increasingly paying attention to the role of astrocytes in spinal cord injury (SCI), degenerative diseases, chronic pain, neurological tumors, and other CNS disorders. In this review, we discuss (a) the characteristics of polarized astrocytes, (b) the relationship between astrocyte polarization and SCI, and (c) new implications of reactive astrogliosis for future SCI therapies.

1. Introduction

Astrocytes are the most numerous cells in the mammalian central nervous system (CNS) and are responsible for various functional and structural roles [1]. Astrocytes regulate blood flow [2, 3], provide energy metabolites to neurons [4], participate in synaptic function and plasticity [1], maintain the balance of extracellular ions and fluids [2], and control neurotransmitter production [5]. The roles of astrocytes in various pathological processes and injuries have been increasingly acknowledged in recent literature [1]. Astrocytes respond to numerous forms of CNS insults through a process referred to as reactive astrogliosis, which has become a pathological hallmark of CNS lesions. For example, reactive astrocytes have been considered a pathological hallmark of many neurodegenerative diseases, including Parkinson’s and Alzheimer’s diseases, as well as amyotrophic lateral sclerosis [6]. Some reports have introduced the role of reactive astrocytes in chronic pain [7]. In 2019, Henrik Heiland et al. reported a type of tumor-associated reactive astrocyte, which aids the progression of glioblastoma through the JAK/STAT pathway [8]. Even in the normal aging brain, reactive astrocytes have been found in certain brain regions [9]. In recent years, researchers have gradually recognized various effects of reactive astrocytes in the process of SCI recovery, including a decrease in the infiltration of inflammatory cells after injury [10]; secretion of related neurotrophic factors [11]; secretion of a significant amount of extracellular matrix, leading to limited nerve repair [12]; and failure to form glial scars, leading to axonal degeneration [13, 14]. Considering the specific process of astrocyte polarization in a wide range of diseases [15, 16], further understanding can shed light on potential directions for future astrocyte therapy. Therefore, in this review, we focus on the development of astrocyte polarization and its relationship with SCI.

2. Astrocyte Reactivity

2.1. Development of the Concept of Astrocyte and Astrocyte Reactivity. The concept of astrocyte was first proposed by Virchow, who described the astrocyte as a kind of cell that surrounds neurons and provides them with nutrients [17]. After the advancement of microscopy and dyeing techniques,
Otto Dieters was the first to visualize astrocytes and provide key descriptions, while Camillo Golgi was the first to prove that astrocytes differ from neurons; however, he also believed that astrocytes and neurons could be transformed from one to the other. Lenhossék introduced the term “astrocyte” in 1895 [18] and developed astrocyte-specific gold and mercury chloride-sublimation staining techniques that label glial fibrillary acidic protein (GFAP); it was this staining that allowed Cajal to discriminate astrocytes from radial glial cells [19]. GFAP and vimentin constitute intermediate filaments, and these components form the basic skeleton of an astrocyte [1]. At the time, GFAP was used as a standard marker for astrocyte reactivity. It is important to mention that GFAP is reportedly expressed in all mammals, but not in fish [20, 21], amphibians [22], turtles [23], and some other nonmammals [16]. Although GFAP may not be the most accurate marker of astrocyte activity, it provides a convenient method of detection. Due to advances in methods for isolating astrocytes and improved understanding of the genetic changes in reactive astrocytes, some new hallmarks of reactive astrocytes have been confirmed, such as Lcn2 and SerpinA3N [24–26]. Interestingly, the concept of modern astrocyte polarization was also proposed by Virchow, who gave a comprehensive description of astrocyte polarization after trauma and neurodegenerative injury [27]. In 2012, Zamanian et al. proposed methods for the formation of two types of reactive astrocytes. The authors elicited the neuroinflammation model by systemic LPS injection and generated an ischemic model by middle cerebral artery occlusion. Using these models, they found two different types of astrocytes that are called A1 and A2 astrocytes, which are similar to the M1/M2 macrophage paradigm [16, 26]. It should be noted that the current naming rules are remarkably simple and that A1 and A2 are not the only types of reactive astrocytes. The naming convention of A1/A2 is used to facilitate scientific research and communication. The function of A1 astrocytes is greatly reduced; for example, there is a lower number of A1 astrocyte-induced synapse formations and the function of these synapses is insufficient. A1 astrocytes highly upregulate the expression of several classical complement cascade genes that were previously shown to be destructive to synapses. Moreover, A1 astrocytes secrete a soluble toxin that rapidly kills a subset of CNS neurons and mature oligodendrocytes but does not affect other CNS cell types [16, 26]. Thus, A1 astrocytes are considered to be a potentially harmful type. In contrast, A2 astrocytes have been shown to upregulate several neurotrophic factors and thus may be a protective type. A2 astrocytes promote the expression of anti-inflammatory cytokine transforming growth factor β (TGF-β) [28]. This factor contributes to axon formation and neuroprotection [29]. Complement component 3 has been found to be specifically elevated in A1 astrocytes, and it is not expressed in A2 astrocytes; thus, it is an effective new marker for detecting A1 astrocytes. S100A10 is a member of the S100 protein family and has been shown to be a specific hallmark for A2 astrocytes. Additionally, S100A10 plays roles in cell proliferation, membrane repair, and inhibition of apoptosis [30].

2.2. Characteristics of Reactive Astrogliosis. In order to determine the roles of astrocytes in the pathology and disorders of the CNS, a large number of recent studies have investigated the functions and mechanisms of reactive astrogliosis. Reactive astrogliosis is not a single stereotypic reaction; in contrast, it is a series carefully regulated changes, including gene expression, cellular hypertrophy, scar formation, and long-term organizational changes [31]. Additionally, reactive astrogliosis is not an all-or-nothing phenomenon, but rather a progressive phenomenon that occurs in a context-dependent manner and that is regulated by specific signaling events. When the initial stimulus to induce astrogliosis is relatively mild, the reactive astrocytes have the ability to return to a relatively normal state after removing the triggering environment [32]. The changes in astrocyte polarization vary with the intensity and type of stimulation. Changes in molecular expression occur at the initial stage, and as the intensity of the stimulus increases, cell hypertrophy, proliferation, and scar formation take place. In a previous study [26], GFAP-stained cerebral cortical mouse cells were used to stimulate the cells by injecting lipopolysaccharides (LPS). As intensity of the stimuli increased, astrocytes overlapped and scars were eventually formed at the site of stimulation. During the polarization of astrocytes, there is a rapid transformation of gene expression. Interestingly, despite the persistent expression of some core genes, at least 50% of the altered gene expression strongly depends on the type of injury [26]. Reactive astrogliosis consists of gene expression and cellular changes that are controlled by complex intercellular and intracellular signals. Currently, it is believed that the most important cellular type that triggers reactive astrogliosis is microglia. In 2017, Liddelow et al. reported that A1 astrocytes are induced by activated microglia [33]. The authors found that three factors, IL-1α, TNFα, and C1q, are produced by microglia and cause astrocyte polarization and that these three factors are essential for LPS-induced in vitro polarization. A single gene knockout test showed that these three factors work together to induce the formation of A1 astrocytes. Microglia do not induce astrocyte polarization when only one or two genes are present. Sonn et al. found that IL-4-induced M2 microglia could stimulate astrocyte activity and chemotaxis of reactive astrocytes in SCI through the Wnt/β-catenin pathway. They observed that the percentage of elongated reactive astrocytes significantly decreased, and the orientation of elongated astrocytes was more random, when the Wnt/β-catenin pathway was inhibited. In contrast, the Wnt pathway agonists enhanced the average protrusion length compared to a control group [34]. Further exploration to determine whether IL-4-induced M2 microglia have the same function will be helpful.

2.3. Morphological Changes in Reactive Astrocytes. Astrocyte polarization induces morphological changes and striking increases in GFAP immunoreactivity [35]. These findings have been interpreted as cellular hypertrophy [35]. It is currently believed that the morphological changes that occur in
reactive astrocytes are mainly the characteristic hypertrophy of the cell body and processes. In addition, the number of protrusions and the length will increase. The morphological changes of reactive astrocytes will vary depending on the type, intensity, and location of the astrocytes at the time of injury (Figure 1). Labeling with GFAP shows that the thickness of processes varies in different types of injuries. For example, the process thickness in cortical and hippocampal injuries increased 2-fold [36]. In an optic nerve crush model, a 0.5-fold increase was observed in the protrusion thickness [37]. However, the thickness of the process was elevated 2.5-fold in an epilepsy injury [38]. Reactive astrocytes exhibit different morphologies as the distance from the lesion core varies. Reactive astrocytes exhibit a typical hypertrophic process and stellate shape without preferential orientation of the protrusion when they are far from the lesion core. However, reactive astrocytes adjacent to the lesion core show a longer process that is oriented towards the damaged core [34].

2.4. Functional Changes of Reactive Astrocytes. At present, accumulating evidence suggests that astrocytes lose their normal physiological functions and gain various abnormal functions during the process of reactive astrogliosis [5, 39, 40]. For example, in Alzheimer’s disease, astrocytes become reactive due to the deposition of amyloid β-protein, and the resulting detrimental consequences include impaired glutamate uptake owing to decreased expression of uptake transporters, altered energy metabolism, altered ion homeostasis (K+ and Ca+), impaired synaptic plasticity, and increased release of cytokines and chemokines [41–43]. Using transgenic mice, which selectively express α-synuclein (a hallmark of Parkinson’s disease) in astrocytes, Gu et al. have shown impaired maintenance of the blood-brain barrier (BBB) and decreased excitatory amino acid transporters of reactive astrocytes [44]. In addition, reactive astrocytes undergo a series of abnormal changes in signaling pathways, such as impaired lactate transport [45], downregulated GLT-1 expression, and sustained calcium ion release in amyotrophic lateral syndrome (ALS). Similarly, reactive astrocytes in ALS also exhibit a malabsorption of glutamate, which is toxic to neurons [6].

Initially, researchers paid greater attention to the detrimental effects of reactive astrocytes in various diseases. Thus, the general belief was that inhibiting the formation of reactive astrocytes would completely block its negative effects. However, as the evidence grows, this simple view no longer remains tenable. Many experiments have shown that reactive astrocytes have positive roles [32]. For example, in GFAP and Vim KO mice, glial scar formation was impaired and less dense scars (frequently accompanied by bleeding) were formed [25, 26]. In 2013, Kraft et al. showed that reactive astrocytes can limit plaque formation in Alzheimer’s disease and reduce plaque-associated dystrophic neurite formation [27]. In cerebral ischemic injury, reactive astrocytes can play a protective role while regulating glutamate transport and control of gap junctions. Specific deletion of reactive astrocytes will increase the degree of damage and neuronal lesions [46].

Although reactive astrocytes do have some positive effects, the abnormal functions of them are more notable. At present, the negative effects of reactive astrocytes mainly include the following: (a) production of proinflammatory chemokines and cytokines [26, 47, 48]; (b) generation of Ca2+ signals [49, 50]; (c) upregulation of aquaporin 4 (AQP4), leading to cytotoxic edema in spinal cord injury and ischemia [51]; (d) elevation of neuroexcitatory glutamate levels [52, 53]; (e) promotion of proliferation and migration or formation of an immunosuppressive environment in glioblastoma [8, 54]; (f) contribution to induction and maintenance of chronic pain [7]; and (g) maintenance and promotion of neurodegenerative diseases [6]. Due to the context-dependent nature of reactive astrocytes, descriptions of their role from different reports of the same disease model may also be different, or they may even be reported to have opposite regulatory effects. Therefore, the function of reactive astrocytes cannot be easily determined, and the pros and cons of reactive astrocytes should be comprehensively evaluated by considering the type of injury, the degree of stimulation, the location of the lesion, and the time after the injury.

2.5. Signaling Pathways and Molecules Triggering Reactive Astrogliosis. Many signaling pathways are related to astrocyte
Intrinsic molecules in reactive astrocytes

Signal transducers
- STAT3, NFκB, JAK2, MAPK, SOX9, mTOR, c-JUN, Olig2, SOC3, PKA, PKC [31, 57]

Receptors
- EGFR, cannabinoid-2 receptor (CB2R), CD36 [76, 77]

MicroRNAs
- miR-21, miR-140, miR-145, miR-17 [65, 78–80]

CNTF: ciliary neurotrophic factor; EGF: epidermal growth factor; ROS: reactive oxygen species; PKA: protein kinase A; PKC: protein kinase C.

Table 1: Signaling pathways and molecules implicated in formation of reactive astrocytes.

| Categories                                      | Molecules                                                                                                                                                                                                 |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Extracellular molecules and signaling pathways  | IL-1β, IL-1α, IL-6, IL-10, IL-17, TNF-α, IFN-γ, CNTF, EGF, Sonic hedgehog (SHH) [32, 70, 71]                                                                                                            |
| Neurodegeneration-associated molecules          | Amyloid-beta, α-synuclein [6]                                                                                                                                                                               |
| Transmitters                                    | Glutamate, noradrenaline [72]                                                                                                                                                                              |
| Oxidative stress molecules                      | NO, ROS [73]                                                                                                                                                                                              |
| Immune-related molecules                         | LPS, Toll-like receptor ligands [74]                                                                                                                                                                        |
| Hormones                                        | Estrogens, glucocorticoids [75]                                                                                                                                                                            |
| Intrinsic molecules in reactive astrocytes      | STAT3, NFκB, JAK2, MAPK, SOX9, mTOR, c-JUN, Olig2, SOC3, PKA, PKC [31, 57]                                                                                                                                  |

Reactivity [55–57]. We summarized these molecules and pathways in Table 1. The most important of these are the NFκB and STAT3 pathways. There is growing evidence that activation of the NFκB pathway leads to pathological changes in the CNS and that inhibition of this pathway helps to limit disease progression [47, 58, 59]. One study demonstrated that selective inactivation of the astrogial NFκB pathway in transgenic mice led to an enormous improvement in the functional recovery after experimental autoimmune encephalomyelitis (EAE) [60]. The STAT3 pathway plays an important role in causing polarization of astrocytes, including in both acute injury and neurodegenerative diseases [61]. Activation of the STAT3 pathway has many functions that are opposed to the NFκB pathway, and it generally contributes to damage repair and cell survival. The STAT3 pathway also plays an important role in scar formation. Conditional knock-out of STAT3 from astrocytes will lead to the downregulation of GFAP, failure of astrocyte hypertrophy, and apparent failure of astrocyte scar formation after SCI in addition to the diffusion of inflammation and impaired motor recovery [62]. Okada et al. revealed the important role of the STAT3 pathway in injury repair. By using mice with a selective deletion of the protein signal (STAT3) or the protein suppressor of cytokine signaling 3 (SOCS3) under the control of the promoter-enhancer, they found that when the STAT3 pathway was inhibited, it caused significant inflammatory cell infiltration, neurological disorders, demyelination, and severe neurological dysfunction. On the contrary, in the activation of the STAT3 pathway, they found that reactive astrocytes migrated rapidly to the lesion and blocked inflammatory cells, increased contraction of tissue in the lesion area, and improved function recovery. These results suggest that STAT3 is a key regulator of reactive astrocytes in the healing process after SCI, thus providing a potential intervention target in the treatment of SCI [10]. In summary, it is probably that reactive astrocytes cause pathological damage through the NFκB pathway and lesion repair and inflammation recovery through the STAT3 pathway (Figure 2). TGF-β signaling is considered another important factor of reactive astrogliosis in SCI. TGF-β signaling has been found to be a key upstream trigger of CSPG expression in glial scar formation [63, 64]. The blood protein fibrinogen, which leaks into the CNS after blood-brain barrier disruption or vascular damage, serves as an important factor for the glial scar formation via the TGF-β signaling pathway. Further, it has also been found that genetic or pharmacologic depletion of fibrinogen in mice reduces TGF-β signaling pathway-activated reactive astrogliosis after SCI. Moreover, injection of fibrinogen into the mouse cortex is sufficient for inducing RAs. In vivo and in vitro inhibition of the TGF-β pathway blocks the function of fibrinogen in the glial scar formation [64]. It is worth mentioning that our team has found that miR-21 regulates reactive astrogliosis by TGF-β signaling at the postacute phase of SCI [65]. More recently, we demonstrated that miR-21 is a switch that regulates the polarization of astrocytes. When miR-21 is downregulated, A1 astrocytes transform into A2 astrocytes. Conversely, when miR-21 is upregulated, A2 astrocytes transform into A1 astrocytes. Furthermore, this function is mediated through the STAT3 pathway. A2 astrocytes regulated by miR-21 promoted synapse formation and neurite growth by targeting Gpc6 and GDNF though the STAT3 signaling pathway [66]. The epidermal growth factor receptor (EGFR) has been found to be a mediator of reactive astrocytes. It is a transmembrane receptor tyrosine kinase that regulates basic cellular functions. After SCI, the EGFR is upregulated primarily in astrocytes at the site of injury and triggers astrocyte polarization [67, 68]. EGFR activation mediates the secretion of growth inhibitory molecules at the site of injury, which can aggravate the formation of glial scars. It has also been shown that treatment with EGFR-specific inhibitors can reduce the formation of glial scars and improve the prognosis. Nucleolin has been shown to interact with epidermal growth factors and to cause an increase in its activation. The use of the nucleolin inhibitor can reduce the activation of EGFR, the proliferation of...
astrocytes, and the secretion of CSPGs, thereby improving the prognosis of SCI [69].

2.6. Genetic and Molecular Changes in Reactive Astrocytes. Previous studies have shown that reactive astrocytes produce many types of intercellular signaling molecules, including cytokines, chemokines, energy metabolism molecules, toxic amino acids, or intracellular signaling molecules including ions and receptors through gene expression (Table 2). These molecules affect themselves and surrounding cells, such as nerve cells, oligodendrocyte precursor cells, and microglia. The expression of genes and molecules of reactive astrocytes is very complicated, and the changes of genes and molecules in different environments also differ. Under the same stimulation, reactive astrocytes in different tissue parts will induce different gene expressions. For example, in different parts of mice with traumatic spinal cord injury, reactive astrocytes were found to express different levels of brain lipid-binding protein (BLBP), GFAP, and nestin [81]. This demonstrates that the astrocyte response to SCI is regionally heterogeneous. Furthermore, only certain types of astrocytes will polarize or be proliferative during the lesion of cortical stab injury [82]. Most of these proliferative cells are located in the juxtavascular sites. Using clonal analysis, the proliferative reactive astrocytes were found to come from different progenitor cells, indicating that the specificity of astrocytes may be decided by distinct cellular origin [83, 84]. This may be related to the birth fate decision of astrocytes, which means that the astrocytes from different sources were carved with their own characteristic at the moment they were produced. Thus, they have slightly different functions, and different gene expressions will also be produced during the polarization of astrocytes. Due to the specificity of the individual cells, whole-transcriptome gene sequencing for population gene expression does not seem to be a good solution to this problem. Single-cell RNA sequencing is a promising method for discriminating the characteristics of different reactive astrocytes.

**Figure 2:** At present, due to the similarity between the NFκB pathway and some of the functions mediated by A1 astrocytes as well as similarities between the STAT3 pathway and some of the actions of A2 astrocytes, it may be that astrocytes transform into A1 through the NFκB pathway and into A2 through the STAT3 pathway. C3: complement component 3; CFB: complement factor B; S100A10: S100 calcium-binding protein A10.

**Table 2:** Molecules and gene expression of reactive astrocytes.

| Categories                          | Intercellular molecules                                      |
|-------------------------------------|-------------------------------------------------------------|
| Cytokines                           | IL-1β, IL-6, IL-10, TNF-α, INF-γ, TGF-α, TGF-β, CNTF, LIF, CLCF1 [26, 63, 64, 85, 86] |
| Chemokines                          | CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL2, CXCL10, CCL12, CXCL20 [87, 88] |
| Amino acids & glutathione            | GABA, glutamate, d-serine [52, 89–92]                       |
| Oxidative stress substances         | ROS, NO, NOS [92–94]                                       |
| Extracellular matrix                | CSPGs, connective tissue growth factor, collagen I, fibronectin, MMP-9 [12, 95, 96] |
| Growth factors                      | VEGF, FGF-2, BDNF, GDNF [71, 97–99]                         |
| Categories                          | Intracellular molecules                                    |
| Transcriptional regulators          | STAT3, NFκB, Olig2, SOX9, mTOR [60, 62, 63, 100, 101]       |
| Receptors & ion channels            | EGFR, KCa3.1, AQP4 [67, 102, 103]                           |
| Intermediate filaments              | Nestin, vimentin, GFAP [16, 88]                             |

BDNF: brain-derived neurotrophic factor; GDNF: glial cell line-derived neurotrophic factor; VEGF: vascular endothelial growth factor; EGFR: epidermal growth factor receptor; MMP-9: matrix metalloproteinase-9; GABA: gamma-aminobutyric acid; CLCF1: cardiotrophin-like cytokine.
3. The Roles of Astrocyte Polarization in SCI

3.1. Introduction to Spinal Cord Injury. SCI is a condition associated with permanent physical disability that requires long-term and complex health care [104]. According to reports, there are 5,000 new patients with traumatic SCI per year in Japan and approximately 17,000 new patients per year in the United States [104, 105]. Etiologically, 90% of cases are caused by violence and accidents, including sport accidents and falls. Clinical manifestations depend on the severity and location of the injury, and the analysis of performance considers partial or complete loss of sensorimotor activity. SCI has a devastating impact on the family of patients, as it prevents them from being economically active. However, despite research on SCI for many years, there is still no effective way to completely restore function of the damaged spinal cord, and more research is needed to understand the mechanisms that reduce inflammation at the injury site and restore spinal cord regeneration. The process of SCI mainly includes primary injury and secondary injury. Primary injury refers to a mechanical SCI caused by vertebral fracture or dislocation. Secondary injury generally occurs within a few minutes after the primary injury and lasts for several weeks or months, causing continuous damage to the spinal cord [106]. Secondary injury can be temporally divided into acute, subacute, and chronic phases. The acute phase occurs quickly after injury and includes astrocyte polarization, vascular damage, ion imbalance, neurotransmitter accumulation, free radical formation, and inflammation [106, 107]. The subacute stage includes apoptosis, demyelination of surviving axons, and matrix remodeling. Finally, the chronic stage includes scar formation and failure of axonal connections [106, 108].

3.2. Detrimental Function of Astrocyte Activity in SCI

3.2.1. Effect of Reactive Astrocytes on Axon Regeneration. The detrimental effects of reactive astrocytes in axonal regeneration mainly include formation of a physical barrier to obstruct axon growth and secretion of inhibitory proteins that impede functional recovery. During the chronic phase of SCI, astrocytes transform into scar-forming astrocytes [109, 110]. Scar-forming astrocytes, microglia, and NG2 glia together form a dense boundary structure around the lesion core to isolate the entire damaged area. After the inflammatory response has stabilized, there are still some other cellular components in the lesion core, including pericytes, perivascular-derived fibroblasts, ependymal cells, and peripheral-derived immune cells [111]. The above components together constitute glial scars. Glial scars are thought to be a mechanical barrier to nerve fiber regeneration and primordial cell regeneration [14]. Among the inhibitory protein factors, chondroitin sulfate proteoglycans (CSPGs) are abundantly expressed by reactive astrocytes and other cells in scar tissue, which are considered major inhibitors of axonal regeneration during this period. Jerry Silver laboratory showed that reactive astrocyte-derived CSPGs in scar tissue after SCI inhibited the growth of axons in vitro, suggesting a possible inhibitory role in vivo [12]. Later, Bradbury et al. showed that injection of chondroitinase ABC, a CSPG-degrading enzyme, into the lesion could inactivate the CSPGs in the scar tissue, which can effectively induce an improvement of motor function [112]. Furthermore, the thermostabilized chABCs have a more effective influence on axonal sprouting and functional recovery after SCI [113]. The results from the Jerry Silver laboratory also showed that axonal growth is prevented when protein tyrosine phosphatase (PTPσ) in axons interact with CSPGs in glial scars. They generated a membrane-forming peptide mimetic of the PTPσ wedge domain that binds to PTPσ and relieves CSPG-mediated inhibition, improving axonal recovery in mice with SCI [114]. Other studies have suggested that inhibiting the formation of CSPGs results in recovery of spinal cord function [115, 116].

3.2.2. Impact of Reactive Astrocytes on Differentiation of Oligodendrocyte Precursor Cells (OPCs). Oligodendrocyte precursor cells (OPCs) are the most proliferative and widely distributed precursor cells in the CNS, which can supplement the large number of oligodendrocytes lost after SCI. Experimental spinal cord injury in rodents proves that oligodendrocyte precursor cells have extremely powerful remyelination ability [84]. Siebert et al. found that CSPGs, particularly when generated following SCI, inhibit OPC process outgrowth and differentiation, which can be completely reversed by chABCs. Therefore, chABC treatment may not only enhance regenerative axonal sprouting but may also enhance remyelination after SCI [117, 118]. In addition to CSPGs, the expression of bone morphogenetic proteins (BMP) is dramatically elevated in reactive astrocytes. Wang et al. found that upregulation of BMP in reactive astrocytes is the main factor that inhibits the differentiation of OPCs. They suggested that the manipulation of BMP signals in endogenous or grafted OPCs may be a useful therapeutic strategy for increasing OPC differentiation and remyelination after SCI [119]. The expression of endothelin-1 (ET-1), which is a secreted signal peptide, can be upregulated in reactive astrocytes. Further, ET-1 can promote the generation of reactive astrocytes in demyelinating tissue [120]. Hammond et al. showed that ET-1 from reactive astrocytes inhibited the differentiation and remyelination of OPCs by activating the Notch pathway [121]. Thus, ET-1 inhibitor maybe a promising target for controlling reactive astrogliosis and improving SCI recovery.

3.3. Positive Function of Reactive Astrocytes in SCI. Of course, in addition to the negative effects of the abovementioned reactive astrogliosis in SCI, there are many positive effects of reactive astrocytes that have been proven or considered. Contrary to what occurs in the chronic state, reactive astrocytes in the acute phase migrate to the lesion and polymerize inflammatory cells to limit the extent of inflammation, a process that plays an important role in the repair of injury. Okada et al. found that astrocytes migrate to the SCI lesion core and limit the infiltrating inflammatory cells. This indicates that, in the acute phase of SCI, astrocytes contribute to the repair of damage and the recovery of motor function [10]. Similarly, selective reactive astrocyte ablation after SCI causes severe leukocyte infiltration, tissue disruption, demyelination, and neuronal death in GFAP-TK transgenic mice.
After SCI, the nerve at the damaged tissue is exposed to a toxic microenvironment, characterized by an imbalance of ionic, amino acids, and high levels of inflammatory substances. This environment has a considerable negative impact on the recovery of the spinal cord. Therefore, the scar tissue formed by reactive astrocytes can block the harmful microenvironment [122]. In the early stage of SCI, glial scar formation was also released nonspecifically into the extracellular environment. Astrocytes were reported to specifically absorb glutamate, thus reducing excitotoxic damage [124]. In addition, glial scars and extracellular matrices stimulate and recruit fibroblasts and endothelial cells, thus also helping to form microvessels at the lesion at a rate which is 50 times higher than that of uninjured areas. Astrocytes have a direct effect on immune cells by secreting immunomodulatory molecules such as TGF-β, TNF-α, and proteoglycans. CSPGs are peripheral components associated with immune activity. They can adhere to growth factors and chemokines required for immune cell growth and recruitment, thereby increasing the concentration of immune cells. Glial scars may also be involved in the proliferation of neural stem cells and progenitor cells. In relation to this, astrocytes are involved in the proliferation of neural progenitor cells and in the regulation of stem cell proliferation and differentiation. CSPGs play a role in the maturation and growth of neural stem cells. Experiments have shown that injection of chABCs into the telencephalic ventricle resulted in a decrease in the number of ventricular cells and self-renewing glial cells.

As mentioned above, the function of reactive astrocytes varies greatly in different situations. Thus, the pros and cons of reactive astrocytes should be analyzed from a dialectical perspective. Different roles of RA in SCI and other CNS disorders are summarized in Table 3.

### 3.4. Disruption of the Function of Reactive Astroglialosis in SCI

Anderson et al.’s team used three genetically targeted loss-of-function manipulations in adult mice and showed that preventing astrocyte scar formation, attenuating scar-forming astrocytes, or deleting astrocyte scars all failed to result in spontaneous regrowth of transected corticospinal tract or sensory recovery in severe SCI. Attenuating scar-forming astrocyte formation indeed hindered the formation of scars, but it cannot cause axonal injuries to reenter the injured area.

Moreover, scar-forming astrocytes have no significant effect on the deposition of CSPGs. Through RNA sequencing, the authors revealed that astrocytes in SCI lesions express multiple axon-growth-supporting molecules. Therefore, they believe that, contrary to the traditional concept, astrocyte scar formation aids rather than prevents CNS axon regeneration after SCI [140]. Later, however, Silver issued a review stating that the statement of Anderson et al.’s team is untenable [141]. Silver pointed out that Anderson et al. stated that reactive astrocytes form the wall containing proteoglycan, thus blocking the regeneration of axons, which is the only reason for the failure of axon regeneration. In turn, blocking this inhibitory effect will cause spontaneous regeneration of axons. There are other potent regeneration-blocking cell types that are present within the lesion core and penumbra. For example, it neglects the immune compartment as well as the cascade of deleterious effects of lesion-derived and damage-induced microglial activation, which may also lead to regeneration [140]. The hypothesis that only removal of astrocytes inevitably leads to spontaneous regeneration is oversimplistic, especially in such an obviously inflammatory environment. The glial scar composition is complex, and simply changing a certain type of cell to influence the repair process may result in an inaccurate representation. The composition of the scar is also a dynamic process that changes over time. As mentioned earlier, scarring composition promotes repair and regeneration during the early stages of formation, but it hinders regeneration in the chronic phase of SCI [142–144]. Many specific aspects of astrocyte polarization have not been clearly confirmed, such as the number of specific polarized cell types, as well as the type of mediator pathway involved in each type and its role when in contact with surrounding inflammatory cells. Understanding these will be of great help in the development of SCI treatment. Importantly, a consideration of the role of reactive astrocytes in SCI should include a comprehensive and correct understanding of their benefits and disadvantages.

### 4. Therapy Related to Reactive Astrocytes in SCI

In 2017, Hara et al. used laser microdissection in combination with immunohistochemistry in a mouse model of contusion SCI to isolate each astrocyte cell type, including naive
astrocytes (NAs), reactive astrocytes (RAs), and scar-forming astrocytes (SAs); as a result, they identified some cell-specific genes. We have listed some characteristics of these cell types in Table 4. In their study, they isolated GFP-positive NAs from primary astrocyte cultures derived from transgenic (CAG-EGFP) mice that ubiquitously express EGFP and transplanted them into the spinal cords of either naive mice or mice with SCI. They then examined the morphological changes of these cells and gene expression. As a result, NAs in the normal spinal cord did not change in either case; however, NAs at the injured spinal cord were polarized. These findings indicate that astrocytes change their phenotype in an environment-dependent manner. Through genetic analysis, Hara et al. also found that genes associated with the extracellular matrix play an important role in the formation of SAs, especially type I collagen (Col1I) genes, which are expressed in the injured spinal cord but not in the normal spinal cord. These findings suggest that type I collagen genes are directly involved in the transformation of RAs into SAs, as well as in astrocytic scar formation, after SCI.

The inhibition of the integrin-mediated RA–Col I interaction prevents astrocytic scar formation via N-cadherin downregulation and promotes axonal regeneration and functional recovery after SCI [142]. In order to express the meaning of this more clearly, we have shown the above process in Figure 3. Polymer nanoparticles (NPs) have a wide range of uses in terms of size, potential surface, and hydrophilic or lipophilic properties and have considerable advantages in drug delivery, which can improve drug selectivity and control long-term drug release. Rolipram is an anti-inflammatory drug that acts on the NFκB pathway in astrocytes. In 2020, Vismara et al. found that rolipram-loaded nanogel (NG) could limit expression of proinflammatory substances, including Lcn2 and iNOS, in A1 astrocytes [145]. Furthermore, NG improved motor functional recovery and reduced reactive astrogliosis in the early stage after SCI. This experiment provides a new insight to future therapeutic treatment of SCI. In a previous section of this review, we mentioned that TGF-β has the ability to prevent astrocyte phenotypic transformation. In vitro use of recombinant human TGF-β3 can rapidly transform A1 into a nonreactive state. Furthermore, recombinant human TGF-β3 has been used in clinical trials to promote skin wound healing and scar healing [146]. Similarly, our team revealed the function of miR-21 in astrocyte activity [65, 66] and found that the formation of A1 astrocytes, as well as increments in the

| Marker gene | Reactive astrocytes | Scar-forming astrocytes |
|-------------|---------------------|------------------------|
| Nestin, Ctnnb1, Plaur, Mmp2, Mmp13, Axin2 (1) | Cdh2, Sox9, Xylt1, Chst11, Csgalnact1, Acan, Pcan, Slit2 (1) | Form astrocytic scar |
| Function | (2) Seclude inflammatory cells | (2) Impede CNS axonal regeneration resulting in limited functional recovery |
| Emergence time | 3 d–14 d | 14 d |
| References | [10] | [14, 148] |

Mmp2: matrix metalloproteinase 2; Chst11: carbohydrate sulfotransferase 11; Csgalnact1: chondroitin sulfate N-acetylgalactosaminyltransferase 1; Acan: aggregan; Slit2: slit guidance ligand 2.

Figure 3: Based on the morphology and function at different stages, astrocytes in SCI are divided into naïve astrocytes, reactive astrocytes, and scar-forming astrocytes. This is a promising method to inhibit the formation of SAs through blockage of the Col1-N-cadherin pathway before the chronic stage of SCI. Nes: nestin; Cdh2: cadherin 2; Sox9: SRY-box transcription factor 9; Xylt1: xylosyltransferase 1; Ctnnb1: catenin beta 1; Plaur: plasminogen activator, urokinase receptor.
production of A2 astrocytes, can be triggered by blocking the miR-21 pathway. Another factor that can be used for the treatment of spinal cord injury is glial-cell-derived neurotrophic factor (GDNF) which, when combined with transplanted Schwann cells, can effectively alleviate the negative effects of RAs after injury. It has been observed that astrocytes migrate to the lesion in large quantities, and the migrated astrocytes are closely related to axons. The processes of astrocyte have been shown to be accompanied by axonal elongation, suggesting that they have a role in repair processes. Notably, GDNF treatment can reduce the production of GFAP and CSPGs [147]. Taken together, the above studies demonstrate that the formation of scar-forming astrocytes can be prevented through a specific pathway before the chronic phase, thereby improving nerve regeneration.

5. Problems and Prospects

We have noticed various aspects of reactive astrogliosis in a broad range of contexts, from SCI and neurodegenerative diseases to tumor, even if the overall understanding of reactive astrocytes is still at an early stage. Importantly, the function of astrogliosis is critical for health and disease. Illustrating the underlying mechanisms involved may shed light on possible cures for a wide range of diseases. Currently, there is a lack of clearly specific markers to distinguish between different types of RAs. In earlier research, various typical markers have been raised, but they have only been useful in a limited number of species. It is unclear whether there are other types or mixed types. Additionally, an in vivo model that integrates the pathological process of reactive astrogliosis in a coherent way is lacking. The existing inflammatory and ischemic models are artificial, and they may neglect some important interactions that occur in vivo. At present, there are several limitations in our understanding of the types of reactive astrocytes, and many questions are still unanswered. What types of astrocytes exist in addition to A1 and A2? Do A1 and A2 astrocytes represent opposite poles; that is, is one beneficial while the other is harmful? Are there intermediate forms between these two? Is the fate of reactive astrocytes related to the difference in their intrinsic genes? The mechanism of A1 formation has been roughly elucidated, but the induction pathway for the formation of A2 astrocytes remains largely unknown. How do reactive astrocytes differentiate into scar-forming astrocytes in SCI? In the face of related issues, single-cell sequencing technology and spatial transcriptomics technology can provide us with partial answers. We can use the fluorescent-activated cell-sorting technique to select specific polarized astrocyte populations for single-cell sequencing and perform spatial transcriptome by slicing different levels of the spinal cord after injury. Compared with traditional sequencing, single-cell sequencing analyzes genes within specific single cell rather than cell populations. The pseudosequence single-cell sequencing technology allows us to understand the various types of polarized cells after SCI and to determine their specific genotypes, as well as to discover more specific markers of polarized cells. Further, we can monitor the dynamic changes of cells like A1 and A2. This will perhaps help us understand how naïve astrocytes transform into scar-forming astrocytes. Further research is needed on the role of reactive astrogliosis in SCI. Are the RAs formed in the acute phase as helpful in SCI recovery as described above? What are the side effects? By the same token, are there only absolute side effects of SAs formed in the chronic phase? What are the adverse effects of blocking it? These questions will drive the direction of future research. There is still a long way to go in this intriguing area of astrocyte reactivity. Fortunately, with the development of technology, more precise separation and purification instruments have emerged. Moreover, microscopy is also rapidly progressing, and we can more clearly observe the specific details of reactive astrocytes, which is of great value for research. We believe that more researchers will join the study of astrocyte polarization, which will greatly promote the progress of this field. The solution to these problems will bring hope to patients with SCI.

6. Conclusions

In this review, we briefly described the roles of astrocytes and the concept and characteristics of astrocyte polarization. Further, we described the roles of astrocytes in SCI and the pathological changes involved. Finally, we explored the implication of astrocytes in the treatment of SCI. The existing evidence supports the hypothesis that scar formation can be reduced by blocking certain pathways, which provides a new direction for future SCI treatment. We also discussed some existing problems in this field and proposed possible solutions. Last but not least, we provided a picture of the future development and prospects in the field of reactive astrogliosis.

Abbreviations

CNS: Central nervous system
GFAP: Glial fibrillary acidic protein
LPS: Lipopolysaccharide
NAS: Naïve astrocytes
SCI: Spinal cord injury
TGF-β: Transforming growth factor β
CSPGs: Chondroitin sulfate proteoglycans
ChABCs: Chondroitin sulfate proteoglycans
PTPσ: Protein tyrosine phosphatase σ
OPCs: Oligodendrocyte precursor cells
BMPs: Bone morphogenetic proteins
RAS: Reactive astrocytes
SAs: Scar-forming astrocytes.

Ethical Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.
Disclosure
The funders participated in the study design, decision to publish, and preparation of the manuscript.

Conflicts of Interest
The authors declare that they have no conflict of interest. B N is a Taishan scholar young expert and director of Jinan Institute of Biomechanics.

Authors’ Contributions
B. Ning and R. Liu designed the research. M. Li, L. Tian, and J. Chen found some paper. X. Li wrote the paper, and B. Ning and R. Liu revised the manuscript. All authors approve of the final version of the manuscript.

Acknowledgments
The authors thank the following funding sources. Grant support was provided by the National Natural Science Funds of China (Nos. 81401014 and 81771346), the Chinese Postdoctoral Science Foundation (Nos. 2014M561935 and 2015T80725), and the Technology Research and Development Program of Jinan City (No. 201704133). The cell model in the picture comes from the Servier Medical Art and BioRender APP.

References
[1] M. V. Sofroniew and H. V. Vinters, “Astrocytes: biology and pathology,” Acta Neuropathologica, vol. 119, no. 1, pp. 7–35, 2010.
[2] G. R. Gordon, S. J. Mulligan, and B. A. MacVicar, “Astrocyte control of the cerebrovasculature,” Glia, vol. 55, no. 12, pp. 1214–1221, 2007.
[3] C. Iadecola and M. Nedergaard, “Glial regulation of the cerebral microvasculature,” Nature Neuroscience, vol. 10, no. 11, pp. 1369–1376, 2007.
[4] L. Pellerin, A. K. Bouzier-Sore, A. Aubert et al., “Activity-dependent regulation of energy metabolism by astrocytes: an update,” Glia, vol. 55, no. 12, pp. 1251–1262, 2007.
[5] B. A. Barres, “The mystery and magic of glia: a perspective on their roles in health and disease,” Neuron, vol. 60, no. 3, pp. 430–440, 2008.
[6] K. Li, J. Li, J. Zheng, and S. Qin, “Reactive astrocytes in neurodegenerative diseases,” Aging and disease, vol. 10, no. 3, pp. 664–675, 2019.
[7] T. Li, X. Chen, C. Zhang, Y. Zhang, and W. Yao, “An update on reactive astrocytes in chronic pain,” Journal of Neuroinflammation, vol. 16, no. 1, p. 140, 2019.
[8] D. Henrik Heiland, V. M. Ravi, S. P. Behringer et al., “Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma,” Nature Communications, vol. 10, no. 1, p. 2541, 2019.
[9] L. E. Clarke, S. A. Liddelow, C. Chakraborty, A. E. Münch, M. Heiman, and B. A. Barres, “Normal aging induces A1-like astrocyte reactivity,” Proceedings of the National Academy of Sciences, vol. 115, no. 8, pp. E1896–e1905, 2018.
[10] S. Okada, M. Nakamura, H. Katoh et al., “Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury,” Nature Medicine, vol. 12, no. 7, pp. 829–834, 2006.
[11] A. Gengatharan, R. R. Bammann, and A. Saghatelian, “The role of astrocytes in the generation, migration, and integration of new neurons in the adult olfactory bulb,” Frontiers in Neuroscience, vol. 10, p. 149, 2016.
[12] R. J. McKeon, R. C. Schreiber, J. S. Rudge, and J. Silver, “Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes,” The Journal of Neuroscience, vol. 11, no. 11, pp. 3398–3411, 1991.
[13] J. M. Gregg, M. A. DePaul, A. R. Filous, B. T. Lang, A. Tran, and J. Silver, “Functional regeneration beyond the glial scar,” Experimental Neurology, vol. 253, pp. 197–207, 2014.
[14] J. Silver and J. H. Miller, “Regeneration beyond the glial scar,” Nature Reviews Neuroscience, vol. 5, no. 2, pp. 146–156, 2004.
[15] H. Fan, K. Zhang, L. Shan et al., “Reactive astrocytes undergo M1 microglia/macrophages-induced necroptosis in spinal cord injury,” Molecular Neurodegeneration, vol. 11, no. 1, p. 14, 2016.
[16] S. A. Liddelow and B. A. Barres, “Reactive astrocytes: production, function, and therapeutic potential,” Immunity, vol. 46, no. 6, pp. 957–967, 2017.
[17] R. von Virchow, Gesammelte abhandlungen zur wissenschaftlichen medicin, Hamm,Grote, 1856.
[18] M. Lenhossek, “Der feinere Bau des Nervensystems im Lichte neuester Forschungen,” in eine allgemeine Betrachtung der Strukturprinzipien des Nervensystems, nebst einer Darstellung des feineren Baues des Rückenmarkes, Fischer, 1895.
[19] V. Garcia-Marín, P. García-López, and M. Freire, “Cajal’s contributions to glia research,” Trends in Neurosciences, vol. 30, no. 9, pp. 479–487, 2007.
[20] E. V. Baumgart, J. S. Barbosa, L. Bally-Cuif, M. Götz, and J. Ninkovic, “Stab wound injury of the zebrafish telencephalon: a model for comparative analysis of reactive gliosis,” Glia, vol. 60, no. 3, pp. 343–357, 2012.
[21] A. Bignami and D. Dahl, “The astroglial response to stabbing. Immunofluorescence studies with antibodies to astrocyte-specific protein (GFA) in mammalian and submammalian vertebrates,” Neuropathology and Applied Neurobiology, vol. 2, no. 2, pp. 99–110, 1976.
[22] Y. H. Hung and D. J. Stelzer, “Frog tectal efferent axons fail to regenerate within the CNS but grow within peripheral nerve implants,” Experimental Neurology, vol. 112, no. 3, pp. 273–283, 1991.
[23] M. Kálmán, H. Somiya, L. Lazarevic, I. Milosevic, C. Ari, and K. Majorossy, “Absence of post-lesion reactive gliosis in elasmobranchs and turtles and its bearing on the evolution of astroglia,” Journal of Experimental Zoology Part B: Molecular and Developmental Evolution, vol. 320, no. 6, pp. 351–367, 2013.
[24] K. Suk, “Lipocalin-2 as a therapeutic target for brain injury: an astrocentric perspective,” Progress in Neurobiology, vol. 144, pp. 158–172, 2016.
[25] S. Lee, J.-Y. Park, W.-H. Lee et al., “Lipocalin-2 is an autoocrine mediator of reactive astrogliosis,” Journal of Neuroscience, vol. 29, no. 1, pp. 234–249, 2009.
[26] J. L. Zamanian, L. Xu, L. C. Foo et al., “Genomic analysis of reactive astrogliosis,” *Journal of Neuroscience*, vol. 32, no. 18, pp. 6391–6410, 2012.

[27] R. Virchow, “Ein Fall von progressiver Muskelatrophie,” *Archiv für Pathologische Anatomie und Physiologie und für Klinische Medizin*, vol. 8, pp. 537–540, 1855.

[28] A. Ruocco, O. Nicole, F. Docagne et al., “A transforming growth Factor-β antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury,” *Journal of Cerebral Blood Flow & Metabolism*, vol. 19, no. 12, pp. 1345–1353, 2016.

[29] L. P. Diniz, I. C. Matias, M. N. Garcia, and F. C. Gomes, “Astrocytic control of neural circuit formation: highlights on TGF-β signaling,” *Neurochemistry International*, vol. 78, pp. 18–27, 2014.

[30] A. Fujita, H. Yamaguchi, R. Yamasaki et al., “Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model,” *Journal of Neuroinflammation*, vol. 15, no. 1, p. 227, 2018.

[31] M. V. Sofroniew, “Astrogliosis,” *Cold Spring Harbor Perspectives in Biology*, vol. 7, p. a020420, 2014.

[32] M. V. Sofroniew, “Molecular dissection of reactive astrogliosis and glial scar formation,” *Trends in Neurosciences*, vol. 32, no. 12, pp. 638–647, 2009.

[33] S. A. Liddelow, K. A. Guttenplan, L. E. Clarke et al., “Neurotoxic reactive astrocytes are induced by activated microglia,” *Nature*, vol. 541, no. 7638, pp. 481–487, 2017.

[34] I. Sonn, M. Nakamura, F. Renault-Mihara, and H. Okano, “Polarization of reactive astrocytes in response to spinal cord injury is enhanced by M2 macrophage-mediated activation of Wnt/β-catenin pathway,” *Molecular Neurobiology*, vol. 57, no. 4, pp. 1847–1862, 2020.

[35] U. Wilhelmsson, E. A. Bushong, D. L. Price et al., “Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury,” *Proceedings of the National Academy of Sciences*, vol. 103, no. 46, pp. 17513–17518, 2006.

[36] U. Wilhelmsson, L. Li, M. Pekna et al., “Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration,” *Journal of Neuroscience*, vol. 24, no. 21, pp. 5016–5021, 2004.

[37] D. Sun, M. Lye-Barthel, R. H. Masland, and T. C. Jakobs, “Structural remodeling of fibrous astrocytes after axonal injury,” *Journal of Neuroscience*, vol. 30, no. 42, pp. 14008–14019, 2010.

[38] D. Sun and T. C. Jakobs, “Structural remodeling of astrocytes in the injured CNS,” *The Neuroscientist*, vol. 18, no. 6, pp. 567–588, 2012.

[39] J. De Keyser, J. P. Mostert, and M. W. Koch, “Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders,” *Journal of the Neurological Sciences*, vol. 267, no. 1-2, pp. 3–16, 2008.

[40] G. Seifert, K. Schilling, and C. Steinhäuser, “Astrocyte dysfunction in neurological disorders: a molecular perspective,” *Reviews in Neuroscience*, vol. 7, no. 3, pp. 194–206, 2006.

[41] B. T. Assefa, A. K. Gebre, and B. M. Altaye, “Reactive astrocytes as drug target in Alzheimer’s disease,” *BioMed Research International*, vol. 2018, Article ID 4160247, 2018.

[42] C. Acosta, H. D. Anderson, and C. M. Anderson, “Astrocyte dysfunction in Alzheimer disease,” *Journal of Neuroscience Research*, vol. 95, no. 12, pp. 2430–2447, 2017.

[43] J. E. Simpson, P. G. Ince, G. Lacc et al., “Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain,” *Neurobiology of Aging*, vol. 31, no. 4, pp. 578–590, 2010.

[44] X.-L. Gu, C.-X. Long, L. Sun, X. Lin, and H. Cai, “Astrocytic expression of Parkinson’s disease-related A53T α-synuclein causes neurodegeneration in mice,” *Molecular Brain*, vol. 3, no. 1, p. 12, 2010.

[45] L. Ferraiuolo, A. Higginbottom, P. R. Heath et al., “Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis,” *Brain*, vol. 134, no. 9, pp. 2627–2641, 2011.

[46] S. Robel, B. Berninger, and M. Götz, “The stem cell potential of glia: lessons from reactive gliosis,” *Nature Reviews Neuroscience*, vol. 12, no. 2, pp. 88–104, 2011.

[47] R. Brambilla, V. Bracchi-Ricard, W. H. Hu et al., “Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury,” *Journal of Experimental Medicine*, vol. 202, no. 1, pp. 145–156, 2005.

[48] M. E. Hamby, G. Coppola, Y. Ao, D. H. Geschwind, B. S. Khakh, and M. V. Sofroniew, “Inflammatory mediators alter the astrocyte transcriptome and calcium signaling elicited by multiple G-protein-coupled receptors,” *Journal of Neuroscience*, vol. 32, no. 42, pp. 14489–14510, 2012.

[49] K. V. Kuchibhotla, C. R. Lattarulo, B. T. Hyman, and B. J. Bacsakai, “Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice,” *Science*, vol. 323, no. 5918, pp. 1211–1215, 2009.

[50] S. Ding, T. Wang, W. Cui, and P. G. Haydon, “Photothrombosis ischemia stimulates a sustained astrocytic Ca2+ signaling in vivo,” *Glia*, vol. 57, no. 7, pp. 767–776, 2009.

[51] Y. Huang, S.-N. Li, X.-Y. Zhou et al., “The dual role of AQP4 in cytotoxic and vasogenic edema following spinal cord concussion and its possible association with energy metabolism via COX5A,” *Frontiers in Neuroscience*, vol. 13, p. 584, 2019.

[52] S.-J. Oh, K.-S. Han, H. Park et al., “Protease activated receptor 1-induced glutamate release in cultured astrocytes is mediated by Bstrophin-1 channel but not by vesicular exocytosis,” *Molecular Brain*, vol. 5, no. 1, p. 38, 2012.

[53] T. Takano, J. Kang, J. K. Jaiswal et al., “Receptor-mediated glutamate release from volume sensitive channels in astrocytes,” *Proceedings of the National Academy of Sciences*, vol. 102, no. 45, pp. 16466–16471, 2005.

[54] J. Wurm, S. P. Behringer, V. M. Ravi et al., “Astrogliosis releases pro-oncogenic Chitinase 3-like 1 causing MAPK signaling in glioblastoma,” *Cancers*, vol. 11, no. 10, p. 1437, 2019.

[55] L. Ben Haim, M. A. Carrillo-de Savage, K. Ceyzériat, and C. Escartin, “Elusive roles for reactive astrocytes in neurodegenerative diseases,” *Frontiers in Cellular Neuroscience*, vol. 9, p. 278, 2015.

[56] A. Buffo, C. Rolando, and S. Ceruti, “Astrocytes in the damaged brain: molecular and cellular insights into their reactive response and healing potential,” *Biochemical Pharmacology*, vol. 79, no. 2, pp. 77–89, 2010.

[57] W. Kang and J. M. Hébert, “Signaling pathways in reactive astrocytes, a genetic perspective,” *Molecular Neurobiology*, vol. 43, no. 3, pp. 147–154, 2011.
[58] R. Brambilla, G. Dvoriantchikova, D. Barakat, D. Ivanov, J. R. Bethea, and V. I. Shestopalov, “Transgenic inhibition of astroglial NF-kB protects from optic nerve damage and retinal ganglion cell loss in experimental optic neuritis,” *Journal of Neuroinflammation*, vol. 9, p. 213, 2012.

[59] R. Brambilla, A. Hurtado, T. Persaud et al., “Transgenic inhibition of astroglial NF-kappa B leads to increased axonal sparing and sprouting following spinal cord injury,” *Journal of Neurochemistry*, vol. 110, no. 2, pp. 765–778, 2009.

[60] R. Brambilla, T. Persaud, X. Hu et al., “Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation,” *Journal of Immunology*, vol. 182, no. 5, pp. 2628–2640, 2009.

[61] S. Hashioka, A. Klegeris, H. Qing, and P. L. McGeer, ""Journal of Neuroinflammation", vol. 11, no. 2, pp. 765–778, 2009.

[62] P. Gris, A. Tighe, D. Levin, R. Sharma, and A. Brown, “Transcriptional regulation of scar gene expression in primary astrocytes,” *Glia*, vol. 55, no. 11, pp. 1145–1155, 2007.

[63] C. Schachttrup, J. K. Ryu, M. J. Helmrick et al., “Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-β after vascular damage,” *Journal of Neuroscience*, vol. 30, no. 17, pp. 5843–5854, 2010.

[64] R. Liu, W. Wang, S. Wang, W. Xie, H. Li, and B. Ning, “MicroRNA-21 regulates astrocytic reaction post-acute phase of spinal cord injury through modulating TGF-β signaling,” *Aging*, vol. 10, no. 6, pp. 1474–1488, 2018.

[65] Y. Su, Z. Chen, H. Du et al., “Silencing miR-21 induces polarization of astrocytes to the A2 phenotype and improves the formation of synapses by targeting glypicann 6 via the transducer and activator of transcription TIP6 pathway after acute ischemic spinal cord injury,” *The FASEB Journal*, vol. 33, no. 10, pp. 10859–10871, 2019.

[66] B. Liu, H. Chen, T. G. Johns, and A. H. Neufeld, “Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury,” *Journal of Neuroscience*, vol. 26, no. 28, pp. 7532–7540, 2006.

[67] B. Liu and A. H. Neufeld, “Activation of epidermal growth factor receptors directs astrocytes to organize in a network surrounding axons in the developing rat optic nerve,” *Developmental Biology*, vol. 273, no. 2, pp. 297–307, 2004.

[68] Y. Goldshmidt, S. Shokoroy Trangle, F. Afergan, T. Iram, and R. Pinkas-Kramarski, “Nucleolin inhibitor GroA triggers reduction in epidermal growth factor receptor activation: pharmacological implication for gli scar formation after spinal cord injury,” *Journal of Neurochemistry*, vol. 138, no. 6, pp. 845–858, 2016.

[69] R. V. Allahyari, K. L. Clark, K. A. Shepard, and A. D. R. Garcia, “Sonic hedgehog signaling is negatively regulated in reactive astrocytes after forebrain stab injury,” *Scientific Reports*, vol. 9, no. 1, p. 565, 2019.

[70] T. You, Y. Bi, J. Li et al., “IL-17 induces reactive astrocytes and up-regulation of vascular endothelial growth factor (VEGF) through JAK/STAT signaling,” *Scientific Reports*, vol. 7, no. 1, p. 41779, 2017.

[71] L. K. Bekar, W. He, and M. Nedergaard, ""Locus coeruleus alpha-adrenergic-mediated activation of cortical astrocytes in vivo,"" *Cerebral Cortex*, vol. 18, no. 12, pp. 2789–2795, 2008.

[72] A. V. Allahyari, K. L. Clark, K. A. Shepard, and A. D. R. Garcia, ""Sonic hedgehog signaling is negatively regulated in reactive astrocytes after forebrain stab injury,"" *Scientific Reports*, vol. 9, no. 1, p. 565, 2019.
Oxidative Medicine and Cellular Longevity

[88] E. Ambrosini, M. E. Remoli, E. Giacomini et al., "Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions," Journal of Neuropathology and Experimental Neurology, vol. 64, no. 8, pp. 706–715, 2005.

[89] S. Li, Y. Uno, U. Rudolph et al., "Astrocytes in primary cultures express serine racemase, synthesize d-serine and acquire A1 reactive astrocyte features," Biochemical Pharmacology, vol. 151, pp. 245–251, 2018.

[90] Y.-H. Lin, H.-Y. Liang, K. Xu et al., "Dissociation of nNOS from PSD-95 promotes functional recovery after cerebral ischaemia in mice through reducing excessive tonic GABA release from reactive astrocytes," The Journal of Pathology, vol. 244, no. 2, pp. 176–188, 2018.

[91] S. Jo, O. Yarishkin, Y. J. Hwang et al., "GABA neuron-derived factor upregulated in glial cells during discord in rats: implications for wound repair and neuroregeneration," Journal of Neurochemistry, vol. 64, no. 8, pp. 706–715, 2005.

[92] Y. Chen, N. E. Vartiainen, W. Ying, P. H. Chan, J. Koistinaho, S. Jo, O. Yarishkin, Y. J. Hwang et al., "GABA neuron-derived factor upregulated in glial cells during discord in rats: implications for wound repair and neuroregeneration," Journal of Neurochemistry, vol. 64, no. 8, pp. 706–715, 2005.

[93] Y.-H. Lin, H.-Y. Liang, K. Xu et al., "Dissociation of nNOS from PSD-95 promotes functional recovery after cerebral ischaemia in mice through reducing excessive tonic GABA release from reactive astrocytes," The Journal of Pathology, vol. 244, no. 2, pp. 176–188, 2018.

[94] S. C. Lee, D. W. Dickson, W. Liu, and C. F. Brosnan, "GABA neuron-derived factor upregulated in glial cells during discord in rats: implications for wound repair and neuroregeneration," Journal of Neurochemistry, vol. 64, no. 8, pp. 706–715, 2005.

[95] J. Saba, J. Turati, D. Ramirez et al., "Astrocyte truncated tropomysosin receptor kinase B mediates brain-derived neurotrophic factor anti-apoptotic effect leading to neuroprotection," Journal of Neurochemistry, vol. 146, no. 6, pp. 686–702, 2018.

[96] M. Duarte Azevedo, S. Sander, and L. Tenenbaum, "GDNF, a neuron-derived factor upregulated in glial cells during disease," Journal of Clinical Medicine, vol. 9, no. 2, p. 456, 2020.

[97] S. Codeluppi, C. I. Svensson, M. P. Heffernan et al., "The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord," Journal of Neuroscience, vol. 29, no. 4, pp. 1093–1104, 2009.

[98] Y. Chen, D. K. Miles, T. Hoang et al., "The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury," Journal of Neuroscience, vol. 28, no. 43, pp. 10983–10989, 2008.

[99] Z. Yu, P. Yu, H. Chen, and H. M. Geller, "Targeted inhibition of KCa3.1 attenuates TGF-β-induced reactive astroglial growth through the Smad2/3 signaling pathway," Journal of Neurochemistry, vol. 130, no. 1, pp. 41–49, 2014.

[100] Z. Zador, S. Stiver, V. Wang, and G. T. Manley, "Role of aquaporin-4 in cerebral edema and stroke," Handbook of Experimental Pharmacology, vol. 190, pp. 159–170, 2009.

[101] A. Ide-Okochi, Y. Yamazaki, E. Tadaka, K. Fujimura, and T. Kusunaga, "Illness experience of adults with cervical spinal cord injury in Japan: a qualitative investigation," BMC public health, vol. 13, no. 1, p. 69, 2013.

[102] D. Lee-Liu, G. Edwards-Faret, V. S. Tapia, and J. Larrain, "Spinal cord regeneration: lessons for mammals from non-mammalian vertebrates," Genesis, vol. 51, no. 8, pp. 529–544, 2013.

[103] C. A. Oyinbo, "Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade," Acta neurobiologiae experimentalis, vol. 71, pp. 281–299, 2011.

[104] R. E. von Leden, Y. J. Yauger, G. Khayrullina, and K. R. Byrnes, "Central nervous system injury and nicotinamide adenine dinucleotide phosphate oxidase: oxidative stress and therapeutic targets," Journal of Neurotrauma, vol. 34, no. 4, pp. 755–764, 2017.

[105] A. P. Tran, P. M. Warren, and J. Silver, "The biology of regeneration failure and success after spinal cord injury," Physiological Reviews, vol. 98, no. 2, pp. 881–917, 2018.

[106] M. T. Fitch and J. Silver, "CNS injury, glial scars, and inflammation: inhibitory extracellular matrices and regeneration failure," Experimental Neurology, vol. 209, no. 2, pp. 294–301, 2008.

[107] S. Okada, M. Hara, K. Kobayakawa, Y. Matsumoto, and Y. Nakashima, "Astrocyte reactivity and astrogliosis after spinal cord injury," Neuroscience Research, vol. 62, pp. 39–43, 2018.

[108] T. M. O'Shea, J. E. Burda, and M. V. Sofroniew, "Cell biology of spinal cord injury and repair," Journal of Clinical Investigation, vol. 127, no. 9, pp. 3259–3270, 2017.

[109] E. J. Bradbury, L. D. Moon, R. J. Popat et al., "Chondroitinase ABC promotes functional recovery after spinal cord injury," Nature, vol. 416, no. 6881, pp. 636–640, 2002.

[110] H. Lee, R. J. McKeon, and R. V. Bellamkonda, "Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury," Proceedings of the National Academy of Sciences, vol. 107, no. 8, pp. 3340–3345, 2010.

[111] B. T. Lang, J. M. Cregg, M. A. DePaul et al., "Modulation of the proteoglycan receptor PTPr promotes recovery after spinal cord injury," Nature, vol. 518, no. 7539, pp. 404–408, 2015.

[112] A. Faisnner, A. Clement, A. Lochtner, A. Streit, C. Mandl, and M. Schachner, "Isolation of a neural chondroitin sulfate proteoglycan with neurite outgrowth promoting properties," The Journal of Cell Biology, vol. 126, no. 3, pp. 783–799, 1994.

[113] L. C. Smith-Thomas, J. Stevens, J. Fok-Seang, A. Faisnner, H. J. Rogers, and J. W. Fawcett, "Increased axon regeneration in astrocytes grown in the presence of proteoglycan synthesis inhibitors," Journal of cell science, vol. 108, Part 3, pp. 1307–1315, 1995.
migration of oligodendrocyte progenitor cells,” *Experimental Neurology*, vol. 231, no. 1, pp. 19–29, 2011.

[118] J. R. Siebert and D. J. Osterhout, “The inhibitory effects of chondroitin sulfate proteoglycans on oligodendrocytes,” *Journal of Neurochemistry*, vol. 119, no. 1, pp. 176–188, 2011.

[119] Y. Wang, X. Cheng, Q. He et al., “Astrocytes from the confused spinal cord inhibit oligodendrocyte differentiation of adult oligodendrocyte precursor cells by increasing the expression of bone morphogenetic proteins,” *Journal of Neuroscience*, vol. 31, no. 16, pp. 6053–6058, 2011.

[120] A. Gadea, S. Schinelli, and V. Gallo, “Endothelin-1 regulates astrocyte proliferation and reactive gliosis via a JNK/c-Jun signaling pathway,” *Journal of Neuroscience*, vol. 28, no. 10, pp. 2394–2408, 2008.

[121] T. R. Hammond, A. Gadea, J. Dupree et al., “Astrocyte-derived endothelin-1 inhibits remyelination through notch activation,” *Neuron*, vol. 81, no. 3, pp. 588–602, 2014.

[122] J. R. Faulkner, J. E. Herrmann, M. J. Woo, K. E. Tansey, N. B. ff, J. R. Siebert and D. J. Osterhout, “Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury,” *Brain Research Bulletin*, vol. 84, no. 4–5, pp. 306–316, 2011.

[123] L. W. Yick, W. Wu, K. F. So, H. K. Yip, and D. K. Shum, “Chondroitinase ABC promotes axonal regeneration of Clarke’s neurons after spinal cord injury,” *Neuroreport*, vol. 11, no. 5, pp. 1063–1067, 2000.

[124] L. M. Carter, S. B. McMahon, and E. J. Bradbury, “Delayed treatment with chondroitinase ABC reverses chronic atrophy of rubrospinal neurons following spinal cord injury,” *Experimental Neurology*, vol. 228, no. 1, pp. 149–156, 2011.

[125] H. Cao and Y.-Q. Zhang, “Spinal glial activation contributes to pathological pain states,” *Neuroscience and Biobehavioral Reviews*, vol. 32, no. 5, pp. 972–983, 2008.

[126] Y.-J. Gao and R.-R. Ji, “Targeting astrocyte signaling for chronic pain,” *Neurotherapeutics*, vol. 7, no. 4, pp. 482–493, 2010.

[127] J. Silver, “The glial scar is more than just astrocytes,” *Experimental Neurology*, vol. 286, pp. 147–149, 2016.

[128] S. Karimi-Abdolrezaee and R. Billakanti, “Selective modulation of reactive astrocytes by type I collagen induces astrocytic scar formation through the integrin-N-cadherin pathway after spinal cord injury,” *Nature Medicine*, vol. 33, no. 7598, pp. 195–200, 2016.

[129] L. X. Deng, J. Hu, N. Liu et al., “Chondroitinase ABC promotes axonal regeneration of A1 astrocytes by drug-loaded nano-structured gel in spinal cord injury,” *Glia*, vol. 66, no. 5, pp. 1065–1080, 2020.

[130] S. Pandit, C. Neupane, J. Woo et al., “Bystrophin1-mediated tonic GABA release from reactive astrocytes prevents the development of seizure-prone network in kainate-injected hippocampi,” *Glia*, vol. 68, no. 5, pp. 1065–1080, 2020.

[131] E. J. Bradbury and L. M. Carter, “Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury,” *Brain Research Bulletin*, vol. 84, no. 4–5, pp. 306–316, 2011.

[132] A. W. Kraft, X. Hu, H. Yoon et al., “Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice,” *The FASEB Journal*, vol. 27, no. 1, pp. 187–198, 2012.

[133] L. M. Carter, S. B. McMahon, and E. J. Bradbury, “Delayed treatment with chondroitinase ABC reverses chronic atrophy of rubrospinal neurons following spinal cord injury,” *Experimental Neurology*, vol. 228, no. 1, pp. 149–156, 2011.

[134] J. Silver, “The glial scar is more than just astrocytes,” *Experimental Neurology*, vol. 286, pp. 147–149, 2016.

[135] M. A. Anderson, J. E. Burda, Y. Ren et al., “Astrocyte scar formation aids central nervous system axon regeneration,” *Nature*, vol. 532, no. 7598, pp. 195–200, 2016.

[136] S. Karimi-Abdolrezaee and R. Billakanti, “Selective modulation of reactive astrocytes by type I collagen induces astrocytic scar formation through the integrin-N-cadherin pathway after spinal cord injury,” *Nature Medicine*, vol. 19, no. 7, pp. 818–828, 2017.

[137] X. Li, B. Yang, Z. Xiao et al., “Comparison of subacute and chronic scar tissues after complete spinal cord transection,” *Experimental Neurology*, vol. 306, pp. 132–137, 2018.

[138] S. Karimi-Abdolrezaee and R. Billakanti, “Selective modulation of reactive astrocytes by drug-loaded nano-structured gel in spinal cord injury,” *ACS Nano*, vol. 14, no. 1, pp. 360–371, 2020.

[139] N. Priego, L. Zhu, C. Monteiro et al., “STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis,” *Nature Medicine*, vol. 24, no. 7, pp. 1024–1035, 2018.

[140] M. A. Anderson, J. E. Burda, Y. Ren et al., “Astrocyte scar formation aids central nervous system axon regeneration,” *Nature*, vol. 532, no. 7598, pp. 195–200, 2016.

[141] E. J. Bradbury and L. M. Carter, “Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury,” *Brain Research Bulletin*, vol. 84, no. 4–5, pp. 306–316, 2011.

[142] M. A. Anderson, J. E. Burda, Y. Ren et al., “Astrocyte scar formation aids central nervous system axon regeneration,” *Nature*, vol. 532, no. 7598, pp. 195–200, 2016.

[143] L. X. Deng, J. Hu, N. Liu et al., “Selective modulation of reactive astrocytes by drug-loaded nano-structural gel in spinal cord injury,” *Glia*, vol. 68, no. 5, pp. 1065–1080, 2020.

[144] S. Karimi-Abdolrezaee and R. Billakanti, “Selective modulation of reactive astrocytes by drug-loaded nano-structural gel in spinal cord injury,” *Glia*, vol. 68, no. 5, pp. 1065–1080, 2020.

[145] L. M. Carter, S. B. McMahon, and E. J. Bradbury, “Delayed treatment with chondroitinase ABC reverses chronic atrophy of rubrospinal neurons following spinal cord injury,” *Experimental Neurology*, vol. 228, no. 1, pp. 149–156, 2011.

[146] J. Silver, “The glial scar is more than just astrocytes,” *Experimental Neurology*, vol. 286, pp. 147–149, 2016.

[147] L. X. Deng, J. Hu, N. Liu et al., “GDNF modifies reactive astrogliosis allowing robust axonal regeneration through Schwann cell-seeded guidance channels after spinal cord injury,” *Experimental Neurology*, vol. 229, no. 2, pp. 238–250, 2011.

[148] S. Karimi-Abdolrezaee and R. Billakanti, “Selective modulation of reactive astrocytes by drug-loaded nano-structural gel in spinal cord injury,” *Glia*, vol. 68, no. 5, pp. 1065–1080, 2020.

[149] L. X. Deng, J. Hu, N. Liu et al., “GDNF modifies reactive astrogliosis allowing robust axonal regeneration through Schwann cell-seeded guidance channels after spinal cord injury,” *Experimental Neurology*, vol. 229, no. 2, pp. 238–250, 2011.